Home Companies Catalysts Deep Dives
Pelacarsen TQJ230 PHASE3
Drug Profile
ModalityAntisense oligonucleotide
RouteSC
Therapy AreaCVRM
Peak Sales Est$4000M
Formulations[]
Companies
NVS (LICENSEE)100%
IONS (ORIGINATOR)0%
Mechanism: Lp(a) reduction
Expert: Antisense oligonucleotide targeting apolipoprotein(a) mRNA
Everyday: Silences a gene to reduce a harmful cholesterol particle
Targets: ["LPA"]
Programs (1)
IndicationStageKey StudyRegional Status
Elevated Lp(a)PHASE3Lp(a)HORIZON[]
Upcoming Catalysts (1)
Pelacarsen - Lp(a) CV Prevention - Ph3 - Topline (HORIZON) H1 2026
Notes
Lp(a)-lowering ASO licensed from Ionis. Phase 3 Lp(a)HORIZON trial ongoing. Potential first-in-class for CV risk reduction.
Data from Supabase · Updated 2026-03-24